Transparency Lists
On this page you can find the list of medicinal products and the relative reference prices including the reduction foreseen pursuant to the AIFA Resolution of 3 July 2006, the further reduction of 5% pursuant to the AIFA Resolution of 27 September 2006, art. 9 paragraph 1, of Law No. 31 of 28 February 2008 (payback) and paragraph 9 of article 11 of Legislative Decree 78/2010 converted with amendments by Law No. 122 of 30 July 2010.
AIFA publishes the lists, in order to allow the Regions and Autonomous Provinces a homogeneous application of the provisions of art. 9, paragraph 5 of Law No. 178 of 8 August 2002.
-
List by active ingredient (November 15, 2024) [3.07 Mb] [PDF] >
-
List by commercial name (November 15, 2024) [2.87 Mb] [PDF] >
-
List in table format (November 15, 2024) [1.85 Mb] [XLS] >
-
List in .csv format (November 15, 2024) [1.59 Mb] [CSV] >
-
New groups added to transparency list (November 15, 2024) [0.41 Mb] [PDF] >
-
Disposizioni AIFA su modalità di rimborso e prescrizione per le specialità a base di calcipotriolo e betametasone (15/09/2023) [0.1 Mb] [PDF] >
-
Determinazione DG/295/2022 - Modifica alla Determinazione DG/166/2021 [0.21 Mb] [PDF] >
-
FAQ - Definizione dei criteri per l'inserimento in lista di trasparenza dei medicinali (aggiornamento del 23/02/2021) [0.16 Mb] [PDF] >
-
Determinazione DG/88/2022 - Definizione dei criteri per l'inserimento in lista di trasparenza [0.23 Mb] [PDF] >
-
Determina 166/2021 - Definizione dei criteri per l'inserimento in lista di trasparenza [5.29 Mb] [PDF] >
-
AIFA provisions on reimbursement and prescription methods for Calcipotriol and Betamethasone-based specialties (15/10/2020) [0.08 Mb] [PDF] >
-
Disposizioni AIFA su modalità di rimborso e prescrizione per le specialità a base di calcipotriolo e betametasone (15/10/2020) [0.08 Mb] [PDF] >
-
Prescribing and of dispensing of pregabalin-based equivalent medicines for the treatment of neuropathic pain (July 13, 2017) [0.09 Mb] [PDF] >
-
Press release for irbesartan and irbesartan/hydrochlorothiazide-based medicinal products (16/11/2016) [0.13 Mb] [PDF] >
-
Reimbursement and prescription procedures for cyclosporine-based medicinal products (January 19, 2016) [0.08 Mb] [PDF] >
-
AIFA clarifications on medicinal products containing cyclosporine (April 15, 2015) [0.16 Mb] [PDF] >
-
AIFA communication on medicinal products containing Levetiracetam and Topiramate (September 17, 2012) [0.12 Mb] [PDF] >
-
AIFA clarifications on medicinal products containing tacrolimus (July 22, 2011) [0.03 Mb] [PDF] >